RxDoctor Payments DataLook up a doctor →

Michael Cammarata, MD

Interventional Cardiology · Boca Raton, FLNPI 1235390535

Payments from drug & device makers

$684,901in general payments, 2019–2025

Across 702 payments — averaging $975.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Withings, Inc.$382K
  • Medtronic$262K
  • Eli Lilly$29K
  • Abbott$4K
  • Novartis$1K
  • Amgen$991
  • plus $6K from 38 others

What the payments were for

  • Consulting fees$250%
  • Travel & lodging$1,2359%
  • Food & beverage$11,85390%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$684,901 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$926,736
Medicare patients
1,536
Services billed
6,861

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban214$275,251
Repatha SureclickEvolocumab120$100,044
XareltoRivaroxaban57$81,243
EntrestoSacubitril/Valsartan48$64,091
MultaqDronedarone Hcl29$54,203
Praluent PenAlirocumab53$28,646
Nebivolol Hcl155$11,324
Rosuvastatin Calcium313$5,143
Flecainide Acetate79$4,437
ClopidogrelClopidogrel Bisulfate212$2,775
Metoprolol Succinate172$2,573
Bisoprolol Fumarate81$2,122
Diltiazem 24hr Er (Cd)Diltiazem Hcl68$2,010
Atorvastatin Calcium184$1,554
Ezetimibe57$1,373

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$779$275,251214 claims
Johnson & JohnsonXarelto$948$81,24357 claims
NovartisEntresto$1,265$64,09148 claims
Sanofi-aventis U.S. LLCMultaq$252$54,20329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →